Accelerate Diagnostics, Inc.
AXDX
$0.70
-$0.0061-0.86%
| Weiss Ratings | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.13 | |||
| Price History | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -32.69% | |||
| 30-Day Total Return | -40.68% | |||
| 60-Day Total Return | -48.15% | |||
| 90-Day Total Return | -60.00% | |||
| Year to Date Total Return | -44.44% | |||
| 1-Year Total Return | -25.55% | |||
| 2-Year Total Return | -89.55% | |||
| 3-Year Total Return | -94.96% | |||
| 5-Year Total Return | -99.07% | |||
| 52-Week High % Change | -66.22% | |||
| 52-Week Low % Change | 2.63% | |||
| Price | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.09 | |||
| 52-Week Low Price | $0.69 | |||
| 52-Week Low Price (Date) | Mar 28, 2025 | |||
| 52-Week High Price (Date) | Sep 03, 2024 | |||
| Valuation | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 17.78M | |||
| Enterprise Value | 68.06M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.21 | |||
| Earnings Per Share Growth | -59.89% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.52 | |||
| Price/Book (Q) | -0.32 | |||
| Enterprise Value/Revenue (TTM) | 5.82 | |||
| Price | $0.70 | |||
| Enterprise Value/EBITDA (TTM) | -2.13 | |||
| Enterprise Value/EBIT | -1.93 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 25.21M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 520 365 3100 | |||
| Address | 3950 South Country Club Road Tucson, AZ 85714 | |||
| Website | acceleratediagnostics.com | |||
| Country | United States | |||
| Year Founded | 1982 | |||
| Profitability | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -301.86% | |||
| Profit Margin | -427.81% | |||
| Management Effectiveness | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -73.66% | |||
| Return on Equity | -- | |||
| Income Statement | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 11.70M | |||
| Total Revenue (TTM) | 11.70M | |||
| Revenue Per Share | $0.46 | |||
| Gross Profit (TTM) | 2.70M | |||
| EBITDA (TTM) | -31.89M | |||
| EBIT (TTM) | -35.31M | |||
| Net Income (TTM) | -50.05M | |||
| Net Income Avl. to Common (TTM) | -50.05M | |||
| Total Revenue Growth (Q YOY) | -6.97% | |||
| Earnings Growth (Q YOY) | 26.23% | |||
| EPS Diluted (TTM) | -2.21 | |||
| EPS Diluted Growth (Q YOY) | 57.34% | |||
| Balance Sheet | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 16.30M | |||
| Cash Per Share (Q) | $0.65 | |||
| Total Current Assets (Q) | 22.24M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -56.04M | |||
| Current Ratio (Q) | 0.713 | |||
| Book Value Per Share (Q) | -$2.23 | |||
| Total Assets (Q) | 28.56M | |||
| Total Current Liabilities (Q) | 31.20M | |||
| Total Debt (Q) | 66.58M | |||
| Total Liabilities (Q) | 84.60M | |||
| Total Common Equity (Q) | -56.04M | |||
| Cash Flow | AXDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -509.00K | |||
| Cash from Financing (TTM) | 27.05M | |||
| Net Change in Cash (TTM) | 2.96M | |||
| Levered Free Cash Flow (TTM) | -4.67M | |||
| Cash from Operations (TTM) | -24.19M | |||
